• Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O, PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. The New England journal of medicine. 2024 Nov 27.
• Edelman EJ, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi VC, Goetz MB, Rodriguez-Barradas MC, Simberkoff MS, Molina PE, Weintrob AC, Maisto SA, Paris M, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial. Journal of acquired immune deficiency syndromes (1999). 2024 Sep 25.
• Painter JT, Pyne J, Curran G, Raciborski RA, Russell S, Fortney J, Gifford AL, Ohl M, Woodward EN. Implementation of collaborative care for depression in VA HIV clinics: Translating Initiatives for Depression into Effective Solutions (HITIDES): protocol for a cluster-randomized type 3 hybrid effectiveness-implementation trial. Implementation science communications. 2024 Sep 16; 5(1):99.
• Murphy NR, Crothers K, Snidarich M, Budak JZ, Brown MC, Weiner BJ, Giustini N, Caverly T, Durette K, DeCell K, Triplette M. A tailored decision aid improves understanding of lung cancer screening in people with HIV. Chest. 2024 Jul 29.
• Soyer EM, McGinnis KA, Justice AC, Hsieh E, Rodriguez-Barradas MC, Williams EC, Park LS. COVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration. AIDS and behavior. 2024 Jul 24.

» View more Citations

• VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
  This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
  
  Date: March 7, 2018
• Evidence Review Identifies Modest Mortality Disparities among Racial and Ethnic Minority Groups in VA Healthcare
  To support VA’s efforts to better understand the scale and determinants of disparities in racial and ethnic mortality – and to develop interventions to reduce disparities, investigators from the VA Evidence-based Synthesis Program (ESP) Coordinating Center in Portland, OR conducted an evidence review of mortality disparities specific to VA. Findings showed that although VA’s equal access healthcar...
  
  Date: March 1, 2018
• Racial Disparities in HIV Quality of Care that May Extend to Common Comorbid Conditions
  To more fully understand patterns of racial disparities in the quality of care for persons with HIV infection, this study examined a national cohort of Veterans in care for HIV in the VA healthcare system during 2013. Findings showed that racial disparities were identified in quality of care specific to HIV infection – and in the care of common comorbid conditions. Blacks were less likely than whi...
  
  Date: September 22, 2016
• New Guidelines May Significantly Decrease Cost for Testing Immune Function in Veterans with HIV
  In 2012, the Department of Health and Human Services recommended CD4 testing in patients with HIV every 3 to 6 months – except in patients with consistently suppressed virus and sustained CD4 cell count, who could be tested every 6 to 12 months. In 2014, updated guidelines recommended that in individuals with viral suppression, CD4 testing be considered either optional or annual, depending on the ...
  
  Date: July 1, 2016
• Consequences of Notifying VA Patients about Potential Exposure to Large-Scale Adverse Events
  This study sought to determine the intended and unintended consequences of patient notification following a large-scale adverse event (LSAE) within the VA healthcare system, which systematically looks for LSAEs, tracks potentially exposed patients, and communicates with them after LSAE notification. Findings showed that more than two-thirds of potentially exposed patients returned for HCV, HBV, an...
  
  Date: May 1, 2015

» View more Publication Briefs

» View more Studies

QUERI Quarterly, June 2005, Vol 7, No 2 (06-23-2005)

QUERI Quarterly, June 2003 (06-24-2003)

» View more Cyberseminars

Videos

There are currently no videos for this topic.

Podcasts

There are currently no podcasts for this topic.

Other Resources

• Visit the HIV/AIDs information section of the VA's Office of Public Health website.
• Visit the Centers for Disease Control & Prevention HIV information section.
• Learn more about all VA research related to HIV on the VA Office of Research & Development’s infectious disease topic page.